- Home
- PACS vs MIRM Comparison
PACS vs MIRM Comparison
Compare PACS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACS | MIRM |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.2B |
| IPO Year | 2024 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PACS | MIRM |
|---|---|---|
| Price | $44.75 | $104.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $45.50 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 849.9K | 553.8K |
| Earning Date | 02-26-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 221.05 | 74.59 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $5,288,932,000.00 | $19,138,000.00 |
| Revenue This Year | $10.19 | $26.22 |
| Revenue Next Year | $8.58 | $22.04 |
| P/E Ratio | $89.00 | ★ N/A |
| Revenue Growth | ★ 29.32 | N/A |
| 52 Week Low | $7.50 | $50.25 |
| 52 Week High | $48.00 | $130.00 |
Technical Indicators
Market Signals| Indicator | PACS | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout PACS PACS Group Inc.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.